RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Acorda Therapeutics - Stock

Acorda Therapeutics Revenue 2024

Acorda Therapeutics Revenue

98.72 M USD

Acorda Therapeutics Dividend yield

Ticker

ACOR

ISIN

US00484M6012

WKN

A0BK80

In 2024, Acorda Therapeutics's sales reached 98.72 M USD, a -16.08% difference from the 117.63 M USD sales recorded in the previous year.

The Acorda Therapeutics Revenue history

YEARREVENUE (undefined USD)GROSS MARGIN (%)
2025e128.2879,79
2024e98.72103,68
2023117.6387,01
2022118.674,37
2021129.168,40
202015378,10
2019192.481,91
2018471.478,94
2017588.376,93
2016519.679,20
2015492.781,12
2014401.579,93
2013336.480,20
2012305.881,16
2011292.277,24
201019181,05
200954.779,16
200847.876,15
200739.578,73
200627.474,09
20055.12006,86
2004-3.9123,08

Acorda Therapeutics Aktienanalyse

What does Acorda Therapeutics do?

Acorda Therapeutics Inc. is a US-based biopharmaceutical company that specializes in researching, developing, and marketing therapeutics for severe neurological diseases. The company was founded in 1995 by Ron Cohen and is headquartered in Ardsley, New York. Acorda Therapeutics started as a small company with few employees and one product, Zanaflex Capsules, a muscle relaxant used for spastic conditions. The company expanded its product portfolio through acquisitions, such as the acquisition of Neuronetrix Solutions, Inc., a company specialized in diagnosing Alzheimer's and other cognitive impairments. Acorda Therapeutics has a business model focused on research and development activities and has formed partnerships with industry experts, academic institutions, and healthcare facilities to support its research efforts. The company has a strong focus on neurology and has expertise in developing protein and antibody-based medications for neurological diseases. Acorda Therapeutics' goal is to meet the needs of patients with severe neurological diseases and develop innovative therapeutics that provide real clinical benefits. The company's main products are Ampyra, an oral medication for improving walking ability in patients with multiple sclerosis, and Zanaflex Capsules, used to treat spastic conditions. Acorda Therapeutics has also developed Inbrija, an inhaled levodopa for treating off-episodes in patients with Parkinson's disease. In addition to medications, the company has developed diagnostic and monitoring devices, such as a device for monitoring vagus nerve stimulation in epilepsy patients, in partnership with Medtronic. Acorda Therapeutics has made significant contributions to the treatment of neurological diseases and has a track record of success in developing collaborative therapies and diagnostic products. While there is still much work to be done, there is hope that continued research and development of new and innovative therapeutics can improve the quality of life for millions of people suffering from severe neurological diseases. Acorda Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Revenue Details

Understanding Acorda Therapeutics's Sales Figures

The sales figures of Acorda Therapeutics originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.

Year-to-Year Comparison

Analyzing Acorda Therapeutics’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.

Impact on Investments

Investors often scrutinize Acorda Therapeutics's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.

Interpreting Sales Fluctuations

Increases in Acorda Therapeutics’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.

Frequently Asked Questions about Acorda Therapeutics Stock

How much revenue did Acorda Therapeutics generate this year?

Acorda Therapeutics has achieved a revenue of 98.72 M USD this year.

How much was the turnover of the company Acorda Therapeutics compared to the previous year?

The revenue of Acorda Therapeutics has increased by -16.08% decreased compared to the previous year.

What does revenue mean for investors?

The revenue of a company is an important indicator of its financial performance and attractiveness for investors.

Which factors influence the revenue of Acorda Therapeutics?

The revenue of Acorda Therapeutics is influenced by various factors, including the demand for its products and services, market conditions, and prices.

How is the revenue of Acorda Therapeutics measured?

Revenue is typically measured in units referring to the sale of goods and services provided by the company.

How does an increase in sales affect investments?

An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.

What are the possible risks associated with a declining revenue?

A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.

Why is the sales revenue of Acorda Therapeutics so important for investors?

The revenue of Acorda Therapeutics is an important indicator of financial performance and attractiveness for investors.

What strategic measures can a company take to increase revenue?

A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.

How much dividend does Acorda Therapeutics pay?

Over the past 12 months, Acorda Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Acorda Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Acorda Therapeutics?

The current dividend yield of Acorda Therapeutics is .

When does Acorda Therapeutics pay dividends?

Acorda Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Acorda Therapeutics?

Acorda Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Acorda Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Acorda Therapeutics located?

Acorda Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Acorda Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Acorda Therapeutics from 6/5/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 6/5/2024.

When did Acorda Therapeutics pay the last dividend?

The last dividend was paid out on 6/5/2024.

What was the dividend of Acorda Therapeutics in the year 2023?

In the year 2023, Acorda Therapeutics distributed 0 USD as dividends.

In which currency does Acorda Therapeutics pay out the dividend?

The dividends of Acorda Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Acorda Therapeutics

Our stock analysis for Acorda Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Acorda Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.